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a  b  s  t  r  a  c  t
Although  RSV  has  been  a high  priority  for vaccine  development,  efforts  to develop  a safe  and  effective
vaccine  have  yet  to lead to a licensed  product.  Clinical  and  epidemiologic  features  of RSV  disease  suggest
there  are  at  least  4  distinct  target  populations  for vaccines,  the RSV  naïve  young  infant,  the  RSV  naïve
child  ≥6  months  of age,  pregnant  women  (to  provide  passive  protection  to newborns),  and  the  elderly.
These  target  populations  raise  different  safety  and  efﬁcacy  concerns  and  may  require  different  vaccination
strategies.  The  highest  priority  target  population  is  the  RSV  naïve  child.  The  occurrence  of  serious  adverse
events  associated  with  the  ﬁrst vaccine  candidate  for young  children,  formalin  inactivated  RSV (FI-RSV),
has  focused  vaccine  development  for  the  young  RSV  naïve  child  on  live  virus  vaccines.  Enhanced  disease  is
not a concern  for  persons  previously  primed  by  a live  virus  infection.  A  variety  of  live-attenuated  viruses
have  been  developed  with  none  yet  achieving  licensure.  New  live-attenuated  RSV  vaccines  are being
developed  and  evaluated  that  maybe  sufﬁciently  safe  and  efﬁcacious  to move  to  licensure.  A variety  of
subunit  vaccines  are  being  developed  and  evaluated  primarily  for  adults  in  whom  enhanced  disease  is
not a concern.  An  attenuated  parainﬂuenza  virus 3  vector  expressing  the RSV  F  protein  was  evaluated
in  RSV  naïve  children.  Most  of  these  candidate  vaccines  have  used  the  RSV  F protein  in various  vaccine
platforms  including  virus-like  particles,  nanoparticles,  formulated  with  adjuvants,  and  expressed  by  DNA
or virus  vectors.  The  other  surface  glycoprotein,  the  G protein,  has  also  been  used  in  candidate  vaccines.
We  now  have  tools  to  make  and  evaluate  a  wide  range  of  promising  vaccines.  Costly  clinical  trials  in
the  target  population  are  needed  to evaluate  and  select  candidate  vaccines  for  advancement  to  efﬁcacy
trials.  Better  data  on RSV-associated  mortality  in developing  countries,  better  estimates  of  the  risk  of
long term  sequelae  such  as wheezing  after  infection,  better  measures  of  protection  in target  populations,
and  data  on the costs  and  beneﬁts  of  vaccines  for  target  populations  are  needed  to  support  and  justify
funding  this  process.  Addressing  these  challenges  and  needs  should  improve  the  efﬁciency  and  speed  of
achieving  a safe  and  effective,  licensed  RSV  vaccine.© 2013 Elsevier Ltd. 
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. Introduction
In preparation for The Decade of Vaccines Collaboration meeting
n Sitges, Spain September 29–30 2011, we developed a case study
or developing vaccines against respiratory syncytial virus (RSV)
n support of the Research and Development Working Group. The
urpose of this case study is to highlight challenges and opportu-
ities for RSV vaccine development and identify priority activities
hat can facilitate vaccine development. This summary is based on
he preparation for the meeting, discussions during the course of
he meeting, and subsequent discussions among members of the
SV working group. Although no vaccine has yet been achieved,
dvances in molecular virology, immunology, and vaccinology, and
 better understanding of pathology and pathogenesis, suggest that
n RSV vaccine is within reach. This document identiﬁes priority
reas for future research and other activities to achieve the goal of
 safe and effective RSV vaccine efﬁciently.
. Background
Respiratory syncytial virus (RSV) is a major cause of lower
espiratory tract infections in children worldwide, leading to an
stimated 3 million annual hospitalizations and at least 66,000
eaths per year in children under 5 years of age. Rates of RSV hos-
italizations are similar in developed and developing countries, at
round 1% of children <1 year of age [1–3]. Mortality from RSV infec-
ion primarily occurs in developing countries, where the estimates
re uncertain with the most recent ones being those noted above.
The burden of RSV globally has kept it a high priority for vac-
ine development. After nearly 50 years of attempts, there is still
o licensed vaccine and there remain challenges to achieving a
afe and effective licensed product. In this paper, we have outlined
hallenges to vaccine development and identiﬁed areas for future
esearch or investigation that we believe are likely to improve the
hance of achieving a safe and effective licensed vaccine. There are
ther sources including some recent reviews [4–8] to which readers
hould refer for more in depth discussions of the virus, its clinical
nd epidemiologic features, pathogenesis of disease, immunity to
he virus, and vaccine platforms.
RSV is a negative sense, non-segmented RNA virus of the family
aramyxovirdae and subfamily Pneumonvirinae. Its genome has 10
enes that encode 11 proteins of which two surface glycoproteins,
 and G, appear to be most important to inducing a protective
mmune response and one, the other, or potentially both will need
o be included in an effective RSV vaccine. RSV infects more than
0% of children during the ﬁrst year of life and the vast major-
ty by 2–3 years of age [9–11]. Primary infections tend to cause
he most severe disease but reinfections and severe disease occur
hroughout life [12]. The young infant and those with compromised
ardiac, pulmonary, or immune systems as well as the elderly are
t greatest risk of severe disease [13,14]. The highest frequency
f RSV-associated hospitalization in most studies is in children <6 . . . .  . . .  . . . . .  .  .  . .  .  . . . . .  . .  . . . . . . .  .  . . . .  . . .  .  . . .  . . .  .  .  . . . . .  .  .  .  .  .  . . . . . . . . . .  .  . .  .  . B214
months of age (peaking at 2–3 months of age) followed by older
children (6–12 months of age), and there is substantial disease up
to 5 years of age [1,2,15,16].  Disease in older children appears to
be especially important in developing countries [2,10,17,18]. As
illustrated by recent studies in Southern Africa, HIV-infected young
children should be included in higher risk populations. In these
studies HIV-infected children have at least a two-fold increase in
rates of RSV lower respiratory tract hospitalization compared to
HIV uninfected children[17,19].
3. Target populations
The epidemiology and burden of RSV disease suggest that there
are at least 4 distinct target populations for RSV vaccines: infants
(<6 months of age) (highest risk of severe disease), children ≥6
months of age (both to prevent their disease and potential trans-
mission to younger children and the elderly), pregnant women
(to protect newborns both by transplacental transfer of antibodies
and by blocking transmission), and the elderly (Table 1). Another
vaccination strategy is to target those who can transmit the virus
to high-risk persons or groups in the community. For example,
vaccination might be used to block transmission from older sib-
lings or other family members to infants or young children in the
household; from health care workers to patients in the healthcare
settings; or from children to the elderly.
The safety and efﬁcacy concerns for each target population or
vaccine strategy are different. Thus, there are likely opportunities
for more than one type of vaccine, and choosing the target popu-
lation best suited for a given vaccine or vaccine platform will be
important to the vaccine’s chances for success.
3.1. Infants (≤6 months of age)
The highest priority target population has been infants. Since
several important transitions in RSV immunity occur at varying
times in different infants, e.g. maturation of the infant immune sys-
tem, waning of transferred maternal antibodies, and the ﬁrst RSV
infection, there is considerable heterogeneity in the immune sta-
tus of infants and young children. Thus, the age of <6 months for
this target population may  need to be revised for different sett-
ings, for different vaccine platforms, and with new information
on the duration of maternally acquired antibody and maturation
of the immune system. Although RSV has been a high priority
for vaccine development for this population for nearly 50 years,
no vaccine is yet available. The ﬁrst candidate vaccine, formalin-
inactivated RSV (FI-RSV), was  associated with enhanced disease
and two  deaths upon subsequent natural RSV infection [20–23].
This occurred in children under 2 years of age but not in older
children, possibly because among the older children prior natural
infection established a safer immune response pattern prior to vac-
cination. These experiences directed development of RSV vaccines
for the RSV-naïve child (mostly among infants) away from subunit
L.J. Anderson et al. / Vaccine 31S (2013) B209– B215 B211
Table  1
Key target populations for an RSV vaccine.
Target population Key considerations Primary vaccine approaches
0–6 months old infants Goal: prevent serious complications of infection
Rationale: highest rate of hospitalization
Challenges:  presence of maternal antibody; immature immune system;
susceptibility to RSV disease; history of FI-RSV enhanced disease
(1) Live-attenuated RSV
(2) Live chimeric virus vectors
(3) Gene-based vectors
(4) Potential for boosting sero-negative infants
with subunit protein or particle-based vaccine
after priming with live or gene-based vector
vaccines
6–24  months old children Goal: prevent serious complications of infection and reduce transmission
to  at-risk household contacts
Rationale: ∼ 50% of childhood hospitalizations occur after 6 months of age;
maternal antibody has waned; less susceptible to severe RSV disease and
more mature immune system than younger children; potential to decrease
transmission to others
Challenges:  clinical endpoint may  be more difﬁcult to achieve than in
neonates; history of FI-RSV enhanced disease
(1) Gene-based vectors
(2) Live-attenuated RSV
(3) Live chimeric virus vectors
(4) Potential for immunizing RSV-seropositive
children with subunit protein or particle-based
vaccine or boosting sero-negative children
after priming with live or gene-based vector
vaccines
Pregnant women  or
women of child-bearing
age
Goal: increase passive antibody protection to fetus and prevent disease at
most vulnerable age; block mother to infant transmission
Rationale: high titer neutralizing antibody protects; can delay vaccination
to  older less vulnerable child with more mature immune system
Challenges:  having experienced multiple previous infections may  limit
response to vaccination; need for substantial increase in antibody levels to
protect the infant; quantify the relationship between neutralizing
antibody level and degree of protection
(1) Subunit protein with standard adjuvants
(2) Particle including VLP  with standard
adjuvants
Adults >65 years Goal: protect from serious complications of infection
Rationale: substantial RSV-associated disease in elderly population
Challenges:  having experienced multiple previous infections may  limit
 prote
ck of c
(1) Subunit protein with novel adjuvant
(2)  Particle including VLP  with novel adjuvant
(3) Gene-based vector with subunit protein or
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eresponse to vaccination; need to improve on
natural infection; difﬁcult to diagnose and la
severity of RSV disease
nd inactivated virus vaccines and toward live virus vaccines [4].
SV infection in the infant, as well as young children, has also been
inked to later reactive airway disease, though a causal relation-
hip has not been established [24]. The infant presents challenges
o vaccine development including an immature immune system
16] that may  not respond well to a vaccine, possibility of recog-
ized or unrecognized risk factors such as cardiac or lung disease
r compromised immune systems, and elevated susceptibility to
isease with live RSV infection. The lack of precise measures of dis-
ase severity makes assessing impact on disease in vaccinees, the
oal of immunization for this population, more difﬁcult.
.2. Young children ≥6 months of age
Since many children >6 months of age will be RSV naïve, the
ssues and concerns regarding vaccines for young children >6
onths of age are similar to those for the infant. The potential
dvantages of this target population include (1) having a more
ature immune system and lower levels of maternal acquired anti-
ody, making them more likely to have good responses to vaccines,
nd (2) likely being less susceptible to adverse respiratory events
rom infection with a live RSV vaccine. Though the preventable dis-
ase is less than that for the infant, it is probably sufﬁciently large
o justify vaccination [1,15].
.3. Pregnant women
The primary goal for vaccinating pregnant women is to induce
igh levels of neutralizing antibodies that will be transferred to her
etus and protect the infant during the highest risk early months
f life. The success of RSV immune prophylaxis [25] demonstrates
hat passive transfer of a sufﬁciently high titer of neutralizing anti-
ody is likely to be protective. The potential for passive protection
n the newborn is also supported by data on decreasing risk of dis-
ase in infants whose mothers had high titers of RSV neutralizingction provided by
lear indicators of the
particle boost
antibodies [26–28].  Another potential beneﬁt of maternal immu-
nization is preventing transmission from the mother to her infant.
Live RSV vaccines have not been immunogenic in adults, and sub-
unit vaccines are being considered for this target population. Since
all adults have been infected by RSV multiple times, they are not
considered at risk for vaccine-induced enhanced disease.
3.4. Elderly adults
Elderly adults have substantial burden of RSV disease, and this
burden increases with underlying cardiac and pulmonary con-
ditions [13]. A challenge to effective vaccination in the elderly
population is immune senescence, which likely will make it more
difﬁcult to induce an effective immune response. Live-attenuated
RSV vaccines have not been immunogenic in adults and subunit
vaccines are being considered for this target population. Elderly
persons most likely to beneﬁt are often also those least able to
respond to vaccination. The frequent presence of co-morbid con-
ditions and lack of precise measures of disease severity make
assessing impact on disease severity, the goal of vaccination in this
population, more difﬁcult.
3.5. Preventing RSV transmission
Another potential use for an RSV vaccine is preventing trans-
mission to high-risk populations. Further study is needed to
understand transmission in the community and the sources of
spread to at-risk populations. Dynamic transmission models could
be used to predict the potential impact of vaccination on transmis-
sion and help identify ways to study this effect [29]. Potential target
populations to prevent transmission include health care workers
caring for high risk patients; older children with infants and young
children in their household; parents of young children; and chil-
dren and workers in day care centers. To be successful, a vaccine
will need to boost existing immunity to sufﬁciently high levels to
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revent infection or decrease the risk of transmission if infection
ccurs. Of vaccines studied to date, the subunit vaccines appear
ost likely to achieve this goal. The tools to detect infection in vac-
inees and in contacts are available and should meet the needs for
ssessing a vaccine’s ability to prevent transmission, the goal of this
accine.
. RSV vaccines
Each type of vaccine and vaccine platform presents different
hallenges and opportunities. It has been difﬁcult to achieve the
ight balance of safety and immunogenicity/efﬁcacy for live atten-
ated RSV vaccines. These vaccines are, however, not considered a
isk for inducing enhanced disease with subsequent RSV infection.
ultiple attenuated viruses have been developed and evaluated as
andidate live virus vaccines and not pursued. Others, including
hose noted below, are in various stages of development and eval-
ation. There are examples of both over- and under-attenuation
n infants with under-attenuation being especially a concern for
he very young infant, e.g. those 0–2 months [30–32].  A variety
f attenuation strategies continue to be tried (e.g. deleting genes
ssociated with immune response modulation or adding additional
utations associated with temperature sensitivity). Studies of the
iology of infection and pathogenesis of disease in humans may
uggest new and better ways to ensure the safety of a live virus
accine and improve efﬁcacy, but ﬁnding a single virus that will
eet the diverse safety and efﬁcacy needs of young children will
emain a challenge. Clinical trials of new candidate live virus vac-
ines such as MEDI-559 (a live-attenuated RSV candidate vaccine)
re continuing. Note that a live virus vaccine given intramuscu-
arly at a relatively low dose was safe though not effective [33].
SV given intramuscularly would have limited ability to replicate,
nd would likely not be immunogenic in persons with pre-existing
SV-speciﬁc antibody.
A variety of subunit RSV vaccines have also been developed [4].
he RSV F and G proteins are the only RSV proteins that induce
eutralizing antibodies, best at inducing protective immunity in
nimals, and likely key components of a vaccine [8].  The F protein
as been noted to induce higher levels of neutralizing antibodies
nd better protective immunity, be more conserved among RSV
trains, and provide better cross-protection against different RSV
trains than the G protein. The G glycoprotein is highly glycosylated
nd variable with the exception of the central region of the pro-
ein. Most candidate vaccines have focused on inducing antibodies
gainst the RSV F protein. The success of passive antibody pro-
hylaxis with an anti-F protein neutralizing monoclonal antibody
25,34,35] provides the proof-of-concept that a vaccine inducing
ufﬁciently high levels of neutralizing antibodies to the F glycopro-
ein should prevent RSV disease.
Several approaches for simulating the antigen presentation
hat occurs during live RSV virus infection have been developed,
eading to candidate vaccines such as virus vectors, gene-based
ectors, replicons, and DNA plasmids [4].  Such candidate vaccines
re designed to simulate the safe pattern of immune responses
nduced by live RSV infection, but without the risk of being insuf-
ciently attenuated. These vaccines are intended to diminish the
isk of enhanced disease in the RSV-naïve infant and young child
hat may  occur when immunogens are processed as extracellular
roteins or particles through MHC  class II presentation pathways.
n addition, these types of vaccines aim to avoid the problems
f pre-existing immunity and potential for immune evasion and
odulation associated with the live-attenuated RSV virus vaccine
andidates. A bovine parainﬂuenza virus 3 expressing RSV-F (MEDI-
34) has been studied in RSV-naïve infants and young children and
ot noted to cause enhanced disease [36].1S (2013) B209– B215
A number of subunit vaccines that contain puriﬁed or expressed
viral proteins have been developed and found to be safe in RSV-
primed older children and adults [4].  The safety of these vaccines
in older children and adults follows from the FI-RSV vaccine trials
in which older children were not at risk from this vaccine and from
animal model studies showing that prior live virus infection pre-
vented FI-RSV enhanced disease [20–23,37].  Presumably, priming
with live RSV infection patterned for a safe immune response and
prevented the disease enhancing response. Though safe, protein
subunit vaccines in older children and adults have demonstrated
only modest immunogenicity as indicated by antibody responses
[38,39]. New F protein-based vaccines include those expressed as
virus-like particles, incorporated into nanoparticles, or formulated
with adjuvants with the hope of enhancing the protective immune
response. One such vaccine, based on an insect cell-expressed F gly-
coprotein, is in early stage clinical trials. These vaccines have not
been tested in RSV-naïve young children.
Although the clinical experience with passive antibody prophy-
laxis and protection in animals has focused vaccine development on
the F protein, the contribution of other viral proteins to immunity
and pathogenesis of disease should also be considered in designing
future vaccines. For example, internal proteins like N, M,  and M2-1
are rich in T cell epitopes and, if delivered by recombinant vectors,
might improve vaccine-induced T cell mediated immunity [4,40].
The G protein appears to play an important role in virus-induced
host inﬂammatory responses that contribute to disease. G-speciﬁc
antibodies might be used to bind G and block its ability to induce
host inﬂammatory responses associated with disease [41]. Since
both F and G induce neutralizing antibodies and protective immu-
nity, a combination of F and G might improve the effectiveness of
a vaccine. The small hydrophobic (SH) protein of RSV is thought
to be a pentameric ion channel analogous to the M2 protein of
inﬂuenza and is another vaccine antigen that should be considered.
While these proteins are not targets for neutralizing antibody, other
mechanisms like ADCC (antibody dependent cell-mediated cyto-
toxicity) might be elicited and contribute to protective immunity.
A major challenge to making progress in developing an RSV
vaccine is translating promising results from in vitro and animal
studies to humans. In vitro and animal model data have identiﬁed
a number of promising candidate vaccines, but none has had a simi-
lar level of success in humans. At present, the only true indication of
a candidate vaccine’s safety and efﬁcacy comes from clinical stud-
ies in the target population. Development of a more permissive and
reliable animal model of disease enhancement could facilitate the
safe testing of a greater variety of candidate vaccines in RSV-naïve
infants.
The challenge of extrapolating from in vitro and animal stud-
ies to humans is compounded by the lack of good measures of RSV
disease severity. The lack of precise measures of disease severity
increases the size and cost of trials to assess the likelihood that a
vaccine will be effective. Although preventing infection, if it can be
achieved with a vaccine, would be a clean, easily measured end
point, studies of passive immune prophylaxis with RSV-speciﬁc
antibodies show that preventing disease can be achieved without
preventing infection. Clinical endpoints, though imprecise, have
and are likely to continue to be a key to deﬁning efﬁcacy. It may
help to devise composite endpoints that include clinical and labo-
ratory measures, e.g. biomarkers, of disease severity for inpatients
and outpatients.
4.1. Challenges and opportunitiesAlthough RSV has confounded efforts to develop a vaccine for
nearly 50 years, the many new molecular, virology, and immunol-
ogy tools now available should make it possible to achieve a safe,
effective, licensed vaccine. Given the substantial public health
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eneﬁt of such a vaccine, we should make every effort to use these
ools most efﬁciently and effectively. The complexities of develop-
ng any new vaccine suggest a coordinated, collaborative approach
hat involves the various public, private and academic partners
s most likely to succeed. We  have identiﬁed barriers that, in
ost instances, apply to the development of any RSV vaccine and,
herefore, should be addressed with a coordinated, collaborative
pproach through the concrete recommendations/actions noted
elow. In anticipation of successful development of an RSV vaccine,
e have also identiﬁed potential barriers to implementation of
accination programs.
.2. The barriers to vaccine development
The failures of RSV vaccines to date and the fact that natural
infection provides limited protection from reinfection and dis-
ease indicate that the task of developing a safe and efﬁcacious
live virus vaccine will be difﬁcult.
Each vaccine target population presents distinct obstacles for RSV
vaccine development.
◦ Infants <6 months of age have maternal antibody that provides
partial protection but also interferes with the immunogenicity
of live virus vaccines and with vectors to which the mother
has antibodies. In addition, infants have an immature immune
system that, among other deﬁciencies, has not fully developed
the capacity for somatic mutation until 4–5 months of age and,
thus, may  respond to immunization with a more limited B cell
repertoire. This very young, RSV-naïve population is considered
at risk for vaccine-mediated disease enhancement.
◦ Many children 6 months to 2 years of age are still RSV-naïve
and, therefore, are also at risk for vaccine-enhanced disease.
Because they are past the peak age of hospitalization, vaccine
developers have had less interest in developing vaccines for this
group.
◦ Pregnant women, as well as older children and all adults will
have pre-existing immunity making it necessary to improve on
existing immunity and ensure that assays can accurately assess
high-titered antibodies without missing responses because of
assay saturation at high titers. For pregnant women, there is
the concern of real or perceived risk to the fetus and potential
vaccine liability for adverse fetal outcomes and the challenge
of developing a program to vaccinate one group only to protect
another group. Immunization of pregnant women  may  provide
limited duration of infant protection, i.e. it is estimated that
each additional month of protection to the infant will require a
doubling of maternal antibody titers. In some populations the
risk of severe disease following RSV infection does not signiﬁ-
cantly decline in the ﬁrst 6 months of life, and maternal boosting
may  have less impact on disease. Maternal immunization may
also decrease risk of RSV transmission from the mother to her
child.
◦ The elderly have preexisting immunity that may  make it
difﬁcult to boost and improve on existing immunity, and
immuno-senescence may  further decrease the effectiveness of
vaccination. In addition, the frequent presence of underlying
disease in elderly populations and short duration of viral shed-
ding make it more difﬁcult to document efﬁcacy.
◦ Lack of data on chains of transmission in many settings makes
developing this vaccination strategy difﬁcult. It will require a
sufﬁcient boost in existing immunity to show a vaccine effect.
There is not an ideal animal model for RSV vaccine evaluation.
Studies of RSV in various animal models have provided important
information on viral and host contributors to disease patho-
genesis and response to candidate vaccines, but it is not clear
how well this information applies to humans. Rodents (mice and
cotton rats) and African green monkeys are semi-permissive to1S (2013) B209– B215 B213
infection; there are not sufﬁcient RSV-naïve chimpanzees avail-
able; and bovine RSV in cattle or pneumonia virus of mice are
surrogate models that do not allow direct testing of the human
vaccine products. There is not yet sufﬁcient experience with
human vaccine testing to conclude how well protection in animal
models predicts protection in humans.
• Clinical studies of candidate vaccines in the target population
are essential to determine which vaccines should be developed
for licensure, but these studies are time consuming and expen-
sive, and resources for these studies are limited. The ability to
measure the impact of vaccine on disease is problematic in all
target populations. Evaluating the impact of the vaccine on clini-
cal endpoints has poor speciﬁcity as clinical presentations of RSV
infections overlap with a range of other viral infections as well
as asthma. Laboratory diagnosis of RSV infection is easiest in the
infant and young child because they have higher titers of virus in
respiratory secretions that are easier to detect. In adults the titers
of virus are lower, and infection is only reliably detected by a rise
in antibody between acute and convalescent serum samples or
by sensitive RT-PCR assays. A decrease in the severity of disease
is the most likely indication that a vaccine is effective. Clinical
and laboratory measures of disease severity are imprecise at all
ages. Imprecise measures of disease outcome compromise meas-
ures of vaccine efﬁcacy and result in the need for larger and more
costly studies.
• Since RSV-primed children and adults are not susceptible to
enhanced disease, lack of enhanced disease in RSV-primed per-
sons does not predict lack of enhanced disease in the RSV-naïve
child, making it difﬁcult to develop safety data to support test-
ing novel RSV vaccines based on non-live virus platforms in the
primary target population (infants <6 months).
• The clinical manifestations of RSV include wheezing and bronchi-
olitis similar to asthma. Because of that, it has been suggested that
RSV may  induce an inﬂammatory response in the host that sig-
niﬁcantly contributes to disease caused by the virus. If that is the
case, there are some concerns that replication-competent vac-
cines may  induce similar responses that may  result in subsequent
airway disease. The risk of vaccine-induced aberrant immune or
inﬂammatory responses may  be speciﬁc to certain groups, e.g.
asthmatics, and suggests the need to evaluate vaccines in various
well-characterized subpopulations.
• Children in developing countries present unique challenges,
including higher frequency of pre-existing HIV infection and par-
asitic disease, higher rates of bacterial co-infection, and economic
and logistical barriers to immunization.
• The lack of data on RSV-associated mortality, predisposition to
subsequent severe respiratory disease in the short term (one
study only [42]) and long term sequelae (risk of subsequent
wheezing) has hindered accurate assessment of the costs and
beneﬁts of RSV vaccines and prioritization of vaccines for dif-
ferent target populations. Lack of good disease burden data is
especially problematic in developing countries where severe
cases and deaths concentrate, but also applies to children any-
where. Also problematic is the lack of good data on the risk of
later reactive airway disease or asthma, the burden of disease in
children >6 months of age, and the risk of older children trans-
mitting virus to others at high risk of disease such as neonates
and the elderly.
• There are limited resources to implement vaccination programs,
and existing commitments for introduction of Haemophilus
inﬂuenza type b, Streptococcus pneumoniae and rotavirus vaccines
in developing countries may  make it more difﬁcult to introduce
and use other vaccines, such as those for RSV.
• The long history of failed vaccine candidates for RSV raises
commercial risks. However, the undeniable medical need and
substantial predicted market support commercial investment.
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Immunization during pregnancy raises liability concerns that
could dampen commercial interest in this approach.
With any vaccine, there is the potential to confuse chance occur-
rence of disease with true vaccine-related adverse events. Data
on backgrounds rates of disease and illness that might be con-
sidered possible adverse reactions to an RSV vaccine, such as
sudden infant death syndrome (SIDS), will make it possible to
assess the likelihood that adverse events are, or are not, related
to the vaccination.
.3. Concrete actions/recommendations for vaccine development
We  feel the following types of research or other activities can
ddress some of the most important challenges and needs noted
bove and by doing so can substantially improve the speed and
robability of success in RSV vaccine development. The follow-
ng recommendations are prioritized by magnitude of impact and
ikelihood of success in the next 3–5 years.
.3.1. Scientiﬁc recommendations: vaccine related
Perform clinical trials with different types of candidate vaccines
in different target populations. Clinical trials provide a unique
and important opportunity to learn about RSV immunity and
disease pathogenesis and provide the means to improve future
candidate vaccines in the same or different target populations.
Maximizing the information gained on response to vaccine, pro-
tective immunity, and disease pathogenesis for all trials should
be a high priority.
Establish precise measures of disease severity to use in assessing
the impact of vaccines on disease for each potential target popula-
tion. Development of clear, precise indicators of disease severity
(e.g. clinical signs and symptoms, virology measures, immune
response measures, biomarkers, etc.) will improve the efﬁciency
and decrease the cost of vaccine trials and will likely increase the
number and variety of types of vaccine evaluated in clinical trials.
Deﬁne the protective and disease enhancing immune responses
associated with natural infection and infection after vaccination,
including correlates of protection in humans. This could include
RSV challenge studies in adults to achieve a deeper understanding
of immunity against reinfection and of factors associated with
boosting existing immunity and achieving durable RSV protective
immunity and to identify virus and host factors that contribute to
pathogenesis of RSV disease. These studies would inform vaccine
design and evaluation.
Develop animal models and in vitro tissue culture systems that
more reliably predict safety and efﬁcacy of vaccines in humans.
.3.2. Scientiﬁc recommendations: epidemiology related
Determine rates of RSV-associated mortality in developing
countries.
Determine the contribution of RSV infection in the infant and
young child to later reactive airway disease.
Model the costs and beneﬁts of vaccinating various target popu-
lations using different vaccine strategies.
Deﬁne chains of transmission to populations at risk from RSV
infection.
.3.3. Commercial recommendations
Because large and costly clinical studies will be required to deter-
mine which candidate vaccines to advance to licensure, new
models for public, non-proﬁt, and industry collaborations and
public-private partnerships are needed to improve the efﬁciency
and decrease the cost of trials and provide mechanisms to share
information gleaned from clinical trials.
Seek novel strategies, such as legislative solutions for no-
fault compensation, to mitigate the liability associated with1S (2013) B209– B215
vaccination during pregnancy, and formulate guidance on the
types of data and studies to assess the safety of protein-based and
other inactivated virus vaccines in RSV-naïve infants and young
children.
• Develop data on rates in the general population of rare adverse
events and disease syndromes that might be confused with
vaccine-induced adverse events.
4.3.4. Programmatic recommendations
• Develop good surveillance and disease burden data for each
potential affected population in different settings to guide
resource allocation decisions.
• Develop educational tools for patients, clinicians, public health
and government leaders about the RSV– disease burden for each
affected population and setting, and articulate the costs and
potential beneﬁts of vaccination.
• Develop transmission models to demonstrate how immunization
of one target population may  protect others (e.g. immunization
of young children protecting neonates and the elderly or immu-
nization of pregnant women  protecting neonates).
5. Summary
The tools that should allow us to develop a safe and effective
RSV vaccine are available and our challenge is to use them wisely.
We believe the concrete actions/recommendations for vaccine devel-
opment noted above can help researchers, funding agencies, and
industry focus their efforts and resources most efﬁciently and effec-
tively.
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